GlassScriptPhysician profile
Colleen Devoe Altman
NPI 1619244142
$3,888.58
in general payments reported to CMS, 2019-2025
49 companies · none reported in 2025
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $745 · 2022: $1,758 · 2023: $1,308 · 2024: $77.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,385.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $416.91 | 2021-2023 | Blincyto, Kyprolis |
| Daiichi Sankyo INC. | $336.39 | 2021-2024 | Enhertu, Vanflyta |
| Novartis Pharmaceuticals Corporation | $271.80 | 2021-2024 | |
| Lilly USA, LLC | $241.89 | 2021-2023 | Verzenio |
| Astellas Pharma US INC | $236.71 | 2021-2023 | Padcev |
| Eisai INC. | $226.43 | 2021-2023 | |
| Seagen INC. | $190.43 | 2021-2023 | Padcev, Tukysa, Tivdak |
| Celgene Corporation | $140.41 | 2021-2023 | Pomalyst, Reblozyl |
| Gilead Sciences, INC. | $127.74 | 2021-2023 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $102.04 | 2021-2023 | Imfinzi |
| Pharmacyclics LLC, An Abbvie Company | $93.66 | 2021-2023 | Imbruvica, Epkinly |
| Incyte Corporation | $92.95 | 2021-2022 | |
| Glaxosmithkline, LLC. | $83.81 | 2022-2023 | Zejula, Jemperli |
| Taiho Oncology, INC. | $81.09 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.57 | 2021-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Altman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.